Part of what makes this question hard to answer is that many people who prioritize their well-being have more than one ...
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custo ...
Contradictory answers from Director of National Intelligence Tulsi Gabbard and CIA Director John Ratcliffe during a Wednesday ...
Director of National Intelligence Tulsi Gabbard explained her shocking presence at the FBI raid of a Georgia elections office ...
Guru Gobind Singh Indraprastha University (GGSIPU) has issued comprehensive guidelines for undergraduate medical admissions for the academic session 2026-27, covering courses such ...
(Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, ...
Stifel 2026 Virtual CNS Forum March 17, 2026 2:00 PM EDTCompany ParticipantsRyan Watts - Co-Founder, President, CEO ...
Roche Holding AG expands Nvidia AI GPUs for drug R&D, tops peers with 3,500+ Blackwell chips, see value vs Eli Lilly and ...
Soligenix Announces HyBryte™ Clinical Summary Published in "Expert Opinion on Investigational Drugs"
(Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, ...
BACKGROUND: Premature atrial contractions (PACs) are independently associated with atrial fibrillation, stroke, and heart failure, yet no pharmacological therapy is approved for PAC suppression.
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results